Modification of the magnetic properties of a drug can be used to direct the drug to the desired site, enhancing its therapeutic effectiveness and reducing side effects. In this study, surface-modified magnetic nanoparticles were immobilized with uracil glucuronide derivatives and then labeled with I-125. The morphology, structure, and composition of the magnetic particles were examined by TEM, SEM, VSM, and XRD. The particles sizes were about 50 nm. The labeling yield was 93.8% for uracil-O-glucuronide-immobilized magnetic particles and 95.0% for uracil-N-glucuronide-immobilized magnetic particles. The cell incorporation rates of N- and O-glucuronides were higher than those of uracil. The incorporation rates of uracil-, O-glucuronide-, and N-glucuronide-conjugated magnetic particles were all high. The cell incorporation rates of ligand-conjugated magnetic particles increased under a magnetic field.